Las Vegas, Nevada
A Comprehensive Clinical Guide for GI and Oncology Nurses
Incorporating NCCN Guidelines and ONS Standards of Practice
Target Audience: Registered Nurses, GI Nurses, Oncology Nurses, Infusion Nurses
Level: Intermediate to Advanced
Release Date: February 2026 | Expiration Date: February 2029
Nevada State Board of Nursing Approved CE Provider
Disclosures and Course Information .................................................. 3
Learning Objectives ........................................................................ 4
Section 1: Overview of GI Malignancies ............................................ 5
Section 2: Colorectal Cancer Treatment ........................................... 8
Section 3: Esophageal and Gastric Cancer ....................................... 12
Section 4: Pancreatic and Hepatobiliary Cancer ............................... 15
Section 5: Chemotherapy Agents for GI Cancers .............................. 18
Section 6: Targeted and Immunotherapy .......................................... 22
Section 7: Safe Handling and Administration ................................... 25
Section 8: Toxicity Management ...................................................... 28
Section 9: Supportive Care and Symptom Management ................... 32
Section 10: Case Studies ................................................................ 35
Complete the exam to earn your CE certificate. You've finished the educational content — now demonstrate your knowledge.
National Comprehensive Cancer Network. NCCN Clinical Practice Guidelines in Oncology: Colon Cancer, Version 1.2025.
National Comprehensive Cancer Network. NCCN Clinical Practice Guidelines in Oncology: Pancreatic Adenocarcinoma, Version 2.2025.
National Comprehensive Cancer Network. NCCN Clinical Practice Guidelines in Oncology: Hepatocellular Carcinoma, Version 1.2025.
Oncology Nursing Society. Chemotherapy and Immunotherapy Guidelines and Recommendations for Practice. 2019.
NIOSH. NIOSH List of Antineoplastic and Other Hazardous Drugs in Healthcare Settings, 2024.
André T, et al. Pembrolizumab in Microsatellite-Instability–High Advanced Colorectal Cancer. N Engl J Med. 2020;383(23):2207-2218.
Finn RS, et al. Atezolizumab plus Bevacizumab in Unresectable Hepatocellular Carcinoma. N Engl J Med. 2020;382(20):1894-1905.
Conroy T, et al. FOLFIRINOX or Gemcitabine as Adjuvant Therapy for Pancreatic Cancer. N Engl J Med. 2018;379(25):2395-2406.
Kelly RJ, et al. Adjuvant Nivolumab in Resected Esophageal or Gastroesophageal Junction Cancer. N Engl J Med. 2021;384(13):1191-1203.
American Cancer Society. Cancer Facts & Figures 2025. Atlanta: American Cancer Society; 2025.
MilenAi Digestive Health Consulting
Nevada State Board of Nursing Approved CE Provider
© 2026 MilenAi Digestive Health Consulting. All rights reserved.
Please complete this evaluation to help us improve future continuing education activities.
Rate each item: 1 = Strongly Disagree, 2 = Disagree, 3 = Neutral, 4 = Agree, 5 = Strongly Agree
___ 1. The learning objectives were clearly stated and met.
___ 2. The content was relevant to my nursing practice.
___ 3. The content was evidence-based and current.
___ 4. The case studies enhanced my understanding.
___ 5. I would recommend this activity to colleagues.
6. I will change my practice by: _______________________________________________
7. Topics for future CE activities: _______________________________________________